Literature DB >> 24795455

Critical role for the NLRP3 inflammasome during acute lung injury.

Jamison J Grailer1, Bethany A Canning1, Miriam Kalbitz1, Mikel D Haggadone1, Rasika M Dhond1, Anuska V Andjelkovic1, Firas S Zetoune1, Peter A Ward2.   

Abstract

The inflammasome is a key factor in innate immunity and senses soluble pathogen and danger-associated molecular patterns as well as biological crystals (urate, cholesterol, etc.), resulting in expression of IL-1β and IL-18. Using a standard model of acute lung injury (ALI) in mice featuring airway instillation of LPS, ALI was dependent on availability of NLRP3 as well as caspase-1, which are known features of the NLRP3 inflammasome. The appearance of IL-1β, a product of NLRP3 inflammasome activation, was detected in bronchoalveolar lavage fluids (BALF) in a macrophage- and neutrophil-dependent manner. Neutrophil-derived extracellular histones appeared in the BALF during ALI and directly activated the NLRP3 inflammasome. Ab-mediated neutralization of histones significantly reduced IL-1β levels in BALF during ALI. Inflammasome activation by extracellular histones in LPS-primed macrophages required NLRP3 and caspase-1 as well as extrusion of K(+), increased intracellular Ca(2+) concentration, and generation of reactive oxygen species. NLRP3 and caspase-1 were also required for full extracellular histone presence during ALI, suggesting a positive feedback mechanism. Extracellular histone and IL-1β levels in BALF were also elevated in C5a-induced and IgG immune complex ALI models, suggesting a common inflammatory mechanism. These data indicate an interaction between extracellular histones and the NLRP3 inflammasome, resulting in ALI. Such findings suggest novel targets for treatment of ALI, for which there is currently no known efficacious drug.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24795455      PMCID: PMC4061751          DOI: 10.4049/jimmunol.1400368

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes.

Authors:  Cristina Andrei; Paola Margiocco; Alessandro Poggi; Lavinia V Lotti; M R Torrisi; Anna Rubartelli
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

2.  Neutrophil extracellular traps kill bacteria.

Authors:  Volker Brinkmann; Ulrike Reichard; Christian Goosmann; Beatrix Fauler; Yvonne Uhlemann; David S Weiss; Yvette Weinrauch; Arturo Zychlinsky
Journal:  Science       Date:  2004-03-05       Impact factor: 47.728

3.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

4.  Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury.

Authors:  Markus Bosmann; Jamison J Grailer; Robert Ruemmler; Norman F Russkamp; Firas S Zetoune; J Vidya Sarma; Theodore J Standiford; Peter A Ward
Journal:  FASEB J       Date:  2013-08-27       Impact factor: 5.191

5.  Activation of NLRP3 inflammasome in alveolar macrophages contributes to mechanical stretch-induced lung inflammation and injury.

Authors:  Jianbo Wu; Zhibo Yan; David E Schwartz; Jingui Yu; Asrar B Malik; Guochang Hu
Journal:  J Immunol       Date:  2013-02-22       Impact factor: 5.422

6.  Role of IL-18 in acute lung inflammation.

Authors:  J A Jordan; R F Guo; E C Yun; V Sarma; R L Warner; L D Crouch; G Senaldi; T R Ulich; P A Ward
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

7.  The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation.

Authors:  Kathy Triantafilou; Timothy R Hughes; Martha Triantafilou; B Paul Morgan
Journal:  J Cell Sci       Date:  2013-04-23       Impact factor: 5.285

8.  Histones trigger sterile inflammation by activating the NLRP3 inflammasome.

Authors:  Ramanjaneyulu Allam; Murthy Narayana Darisipudi; Jurg Tschopp; Hans-Joachim Anders
Journal:  Eur J Immunol       Date:  2013-09-06       Impact factor: 5.532

9.  Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1.

Authors:  M S Mulligan; P A Ward
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

10.  Incidence of acute lung injury in the United States.

Authors:  Christopher H Goss; Roy G Brower; Leonard D Hudson; Gordon D Rubenfeld
Journal:  Crit Care Med       Date:  2003-06       Impact factor: 7.598

View more
  118 in total

1.  Artesunate Inhibits Renal Ischemia-Reperfusion-Mediated Remote Lung Inflammation Through Attenuating ROS-Induced Activation of NLRP3 Inflammasome.

Authors:  Zhaohui Liu; Min Qu; Lili Yu; Panpan Song; Yulin Chang
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

2.  Surfactant inhibits ATP-induced release of interleukin-1β via nicotinic acetylcholine receptors.

Authors:  Sören Backhaus; Anna Zakrzewicz; Katrin Richter; Jelena Damm; Sigrid Wilker; Gabriele Fuchs-Moll; Mira Küllmar; Andreas Hecker; Ivan Manzini; Clemens Ruppert; J Michael McIntosh; Winfried Padberg; Veronika Grau
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

3.  The TWIK2 Potassium Efflux Channel in Macrophages Mediates NLRP3 Inflammasome-Induced Inflammation.

Authors:  Anke Di; Shiqin Xiong; Zhiming Ye; R K Subbarao Malireddi; Satoshi Kometani; Ming Zhong; Manish Mittal; Zhigang Hong; Thirumala-Devi Kanneganti; Jalees Rehman; Asrar B Malik
Journal:  Immunity       Date:  2018-06-26       Impact factor: 31.745

4.  Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA Secretion.

Authors:  Gi S Yoon; Sudha Sud; Rahul K Keswani; Jason Baik; Theodore J Standiford; Kathleen A Stringer; Gus R Rosania
Journal:  Mol Pharm       Date:  2015-06-05       Impact factor: 4.939

Review 5.  Therapeutic targeting of acute lung injury and acute respiratory distress syndrome.

Authors:  Theodore J Standiford; Peter A Ward
Journal:  Transl Res       Date:  2015-05-05       Impact factor: 7.012

6.  The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages.

Authors:  Songlin Yu; Dan Wang; Lingmin Huang; Yening Zhang; Ruiheng Luo; Dickson Adah; Yiting Tang; Kai Zhao; Ben Lu
Journal:  J Biol Chem       Date:  2019-04-10       Impact factor: 5.157

7.  Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice.

Authors:  Yong Zhou; Tian Liu; Jia-Xi Duan; Ping Li; Guo-Ying Sun; Yong-Ping Liu; Jun Zhang; Liang Dong; Kin Sing Stephen Lee; Bruce D Hammock; Jian-Xin Jiang; Cha-Xiang Guan
Journal:  Shock       Date:  2017-05       Impact factor: 3.454

8.  Genetic inactivation of the phospholipase A2 activity of peroxiredoxin 6 in mice protects against LPS-induced acute lung injury.

Authors:  José Pablo Vázquez-Medina; Jian-Quin Tao; Priyal Patel; Renata Bannitz-Fernandes; Chandra Dodia; Elena M Sorokina; Sheldon I Feinstein; Shampa Chatterjee; Aron B Fisher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-01-31       Impact factor: 5.464

9.  TREM-1 Attenuates RIPK3-mediated Necroptosis in Hyperoxia-induced Lung Injury in Neonatal Mice.

Authors:  Mansoor Ali Syed; Dilip Shah; Pragnya Das; Sture Andersson; Gloria Pryhuber; Vineet Bhandari
Journal:  Am J Respir Cell Mol Biol       Date:  2019-03       Impact factor: 6.914

10.  Isoflurane attenuates lipopolysaccharide-induced acute lung injury by inhibiting ROS-mediated NLRP3 inflammasome activation.

Authors:  Ning Yin; Zhendan Peng; Bin Li; Jiangyan Xia; Zhen Wang; Jing Yuan; Lei Fang; Xinjiang Lu
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.